Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 21

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
iluted8,871,155 8,476,231 8,815,414 8,523,223 

See accompanying notes.

2

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Deficit

(Unaudited)

Six Months Ended June 30, 2025AdditionalAccumulatedotherTotalCommon stockpaid-incomprehensiveAccumulatedstockholders'SharesAmountcapitallossdeficitdeficitBalance at December 31, 20248,700,386 $870 $169,705,480 $(428,809)$(175,289,630)$(6,012,089)Stock-based compensation— — 377,357 — — 377,357 Issuance of common stock, net of issuance costs150,000 15 436,233 — — 436,248 Net loss— — — — (4,378,307)(4,378,307)Foreign currency translation adjustments— — — 13,090 — 13,090 Balance at March 31, 20258,850,386 $885 $170,519,070 $(415,719)$(179,667,937)$(9,563,701)Stock-based compensation— — 359,018 — — 359,018 Issuance of common stock, net of issuance costs180,000 18 474,995 — — 475,013 Net loss— — — — (4,016,483)(4,016,483)Foreign currency translation adjustments— — — 12,893 — 12,893 Balance at June 30, 20259,030,386 $903 $171,353,083 $(402,826)$(183,684,420)$(12,733,260)

3

Six Months Ended June 30, 2024AdditionalAccumulatedotherTotalCommon stockpaid-incomprehensiveAccumulatedstockholders'SharesAmountcapitallossdeficitdeficitBalance at December 31, 20238,331,161 $833 $166,548,454 $(360,896)$(171,236,031)$(5,047,640)Stock-based compensation— — 627,700 — — 627,700